JAMA news releases are made available to the public after 3 pm US Central time on the first 4 Tuesdays of each month. The Archives Journals news releases are made available to the public after 3 pm Central time on Mondays. We also provide a list of previous news releases.
JAMA NEWS RELEASES
SPECIAL JAMA COMMENTARY ON LESSONS LEARNED FROM TROUBLES WITH COX-2 INHIBITORS
INFORMATION CONTAINED IN THESE NEWS RELEASES IS PROTECTED BY COPYRIGHT. JOURNAL ATTRIBUTION IS REQUIRED.
Please Note: Our e-mail has changed to
mediarelations{at}jama-archives.org
JOURNALISTS CAN NOW ACCESS EMBARGOED JAMA/ARCHIVES STUDIES ONLINE
Go to www.jamamedia.org for more information and to apply for access.
Please Note: The FOR THE MEDIA Web site now has a search feature to enable media to find previous JAMA/Archives news releases on specific medical topics. This search feature link is located on the home page at www.jamamedia.org
FOR IMMEDIATE RELEASE: 3 P.M. (CT), TUESDAY, DECEMBER 28, 2004
Media Advisory: To contact Eric J. Topol, M.D., call Cole Hatcher at 216-445-1991.
SPECIAL JAMA COMMENTARY ON LESSONS LEARNED FROM TROUBLES WITH COX-2 INHIBITORS
CHICAGO—One of the nation's leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online today by JAMA because of its relevance to the recent withdrawals and warning labels on the pain-relieving drugs known as COX-2 inhibitors. The article will be published in a print edition of JAMA in early 2005.
Eric J. Topol, M.D. from the Cleveland Clinic Foundation, writes that the cardiovascular risks of the various coxib drugs were not well-studied in clinical trials. "Based on data available in 2001 for celecoxib and rofecoxib, my colleagues and I concluded: 'it is mandatory to conduct a trial specifically assessing cardiovascular risk and benefit of these agents. Until then, we urge caution in prescribing these agents to patients at risk for cardiovascular morbidity.' Unfortunately, no such trials were ever initiated and the official warnings for the coxib drugs took years to materialize."
"Importantly, providing more authority to the FDA (Food and Drug Administration) to shape and require the execution of vital trials is perhaps the most important lesson from the coxibs," Dr. Topol writes. "...legislation is needed to empower the FDA to require industry to conduct trials that are deemed necessary to ensure the safety profile of a drug. Had coxib trials been conducted five years ago in patients with established cardiovascular disease, when the benefit and risks were indeterminate, clinicians would have quickly learned the risk and potentially avoided a major cardiovascular calamity. The combination of mass promotion of a medicine with an unknown and suspect safety profile cannot be tolerated in the future. An aggressive position going forward is necessary for not only ensuring the safety of prescription medicines, but also to restore a solid foundation of public trust."
(JAMA. 2005;293:366-368. Available post-embargo at jama.com)
For More Information: Contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or email: mediarelations{at}jama-archives.org
Go back to the top.
